Activity of Pterostilbene Metabolites against Liver Steatosis in Cultured Hepatocytes
dc.contributor.author | Trepiana Arin, Jenifer | |
dc.contributor.author | Krisa, Stéphanie | |
dc.contributor.author | Portillo Baquedano, María Puy | |
dc.date.accessioned | 2020-12-15T09:06:51Z | |
dc.date.available | 2020-12-15T09:06:51Z | |
dc.date.issued | 2020-11-20 | |
dc.identifier.citation | Molecules 25(22) : (2020) // Article ID 5444 | es_ES |
dc.identifier.issn | 1420-3049 | |
dc.identifier.uri | http://hdl.handle.net/10810/49021 | |
dc.description.abstract | Pterostilbene is a dimethyl ether derivative of resveratrol, less metabolized than its analogue, due to the substitution of two hydroxyl groups with methoxyl groups. Nevertheless, the amounts of pterostilbene phase II metabolites found in plasma and tissues are higher than those of the parent compound. The first aim of this study was to assess whether pterostilbene-4′-O-glucuronide (PT-G) and pterostilbene-4′-O-sulfate (PT-S) were able to prevent triglyceride accumulation in AML12 (alpha mouse liver 12) hepatocytes. This being the case, we aimed to analyze the mechanisms involved in their effects. For this purpose, an in vitro model mimicking the hepatocyte situation in fatty liver was developed by incubating mouse AML12 hepatocytes with palmitic acid (PA). For cell treatments, hepatocytes were incubated with 1, 10 or 25 µM of pterostilbene, pterostilbene-4′-O-glucuronide or pterostilbene-4′-O-sulfate for 18 h. Triglycerides and cell viability were assessed by a commercial kit and crystal violet assay, respectively. Protein expression of enzymes and transporters involved in triglyceride metabolism was analyzed by immunoblot. The results showed for the first time the anti-steatotic effect of pterostilbene metabolites and thus, that they contribute to the preventive effect induced by pterostilbene on steatosis in in vivo models. This anti-steatotic effect is mainly due to the inhibition of de novo lipogenesis. | es_ES |
dc.description.sponsorship | This research was funded by Ministerio de Economía y Competitividad-Fondo Europeo de Desarrollo Regional (grant number AGL-2015-65719-R MINECO/FEDER, UE), Instituto de Salud Carlos III CIBERobn (grant number CB12/03/30007) and University of the Basque Country (grant number GIU 18/173). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/AGL-2015-65719-R | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | pterostilbene metabolites | es_ES |
dc.subject | pterostilbene-4′-O-glucuronide | es_ES |
dc.subject | pterostilbene-4′-O-sulfate | es_ES |
dc.subject | liver steatosis | es_ES |
dc.subject | AML-12 hepatocytes | es_ES |
dc.title | Activity of Pterostilbene Metabolites against Liver Steatosis in Cultured Hepatocytes | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2020-11-26T14:11:56Z | |
dc.rights.holder | 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1420-3049/25/22/5444/htm | es_ES |
dc.identifier.doi | 10.3390/molecules25225444 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | |
dc.departamentoeu | Farmazia eta elikagaien zientziak |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).